bovnews13h
Bristol-Myers Squibb Co (BMY) Stock Posted a Gross Margin of 55.87% Over the Past Year: Is This Justifiable?
Jefferies has recently raised Bristol-Myers Squibb Co (BMY) stock to Buy rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the ...
Positive Outlook for Bristol-Myers Squibb with Promising Market Access and Societal Benefits of Cobenfy
Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors
This was the stock's third consecutive day of losses.
bovnews2d
Bristol-Myers Squibb Co (BMY) Stock’s -0.01% Decrease This Year: What’s the Story?
Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $55.74 which represents a slight increase of $0.38 or 0.69% from the prior close of $55.36. The stock opened at $55.5 and ...
Wedmont Private Capital Has $586,000 Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)
Wedmont Private Capital grew its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 29.5% during the 4th ...
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day
The stock's rise snapped a three-day losing streak.
NBC 10 Philadelphia5d
Bristol Myers Squibb CEO describes new drug for treating schizophrenia
Bristol Myers Squibb CEO Chris Boerner described his company's new drug, Cobenefy, which can be used to treat psychiatric disorders like schizophrenia. He said the treatment is effective but doesn ...
Bristol-Myers Squibb (NYSE:BMY) Position Increased by Legacy Private Trust Co.
Legacy Private Trust Co. lifted its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.3% during the 4th quarter, ...
Bristol Myers, ArsenalBio achieve milestone for AB-4000 series
Arsenal Biosciences announced that Bristol Myers Squibb has exercised its exclusive license option for ArsenalBio’s AB-4000 series, the lead collaboration program generated unde ...
Bristol sees annual $1.5B in cost savings by end of 2025
Bristol Myers Squibb CEO Christopher Boerner said $1.5B in annual cost savings should be achieved by the end of the year.